SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The 6-K body explicitly states that on August 4, 2026, AudioCodes issued a press release "announcing financial results for the second quarter of 2026, a semi-annual cash dividend, and other matters," with the press release attached as Exhibit 1. This is a discrete earnings announcement for Q2 2026 results, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →This is a standard earnings release disclosing IDEAYA's financial results for Q2 2026 (ended June 30, 2026), including collaboration revenue of $8.9 million, R&D expenses of $108.7 million, G&A expenses of $22.5 million, and a net loss of $112.5 million. The filing is furnished under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. The release also includes material business updates on clinical trial progress and cash position ($1.24 billion), making it material to investors.
View raw filing on EDGAR →Toyota disclosed FY2027 First Quarter Financial Results for the three-month period ending June 30, 2026, reporting consolidated operating income of 1.063 trillion yen, net income of 1.477 trillion yen, and vehicle sales of 2.411 million units, along with revised full-year FY2027 forecasts.
View raw filing on EDGAR →Waters Corporation announced its Q2 2026 financial results on August 4, 2026, with total reported revenue of $1.645 billion, organic revenue growth of 7% as reported and 9% in constant currency, and adjusted EPS of $3.05. The company also raised full-year 2026 guidance across all components, including organic constant currency revenue growth of 7-9% and adjusted EPS of $14.45-$14.65 (10-12% growth). This is a standard quarterly earnings release with press release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →Trex Company issued a press release on August 4, 2026, announcing financial results for Q2 2026 and six months ended June 30, 2026. The disclosure includes net sales of $418 million, gross margin of 37.9%, net income of $62 million, and diluted EPS of $0.60, along with full-year 2026 guidance reaffirmation and Q3 guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Vivid Seats issued a press release on August 4, 2026 disclosing second quarter 2026 financial results, including Marketplace GOV of $659.4 million, revenues of $129.9 million, net loss of $14.3 million, and adjusted EBITDA of $12.6 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes condensed consolidated financial statements and forward guidance for full-year 2026.
View raw filing on EDGAR →This is a clear earnings release disclosing United Parks & Resorts Inc.'s financial results for Q2 and first six months of fiscal 2026. The filing explicitly states it is "issued a press release announcing the results of the Company's operations for the second quarter ended June 30, 2026" and is furnished under Item 2.02 of Form 8-K. The press release includes detailed financial metrics (total revenue of $483.3M for Q2, net income of $63.3M, Adjusted EBITDA of $195.5M) and operational highlights (6.1M attendance, per-capita spending metrics), which are material to investors assessing the company's operating performance.
View raw filing on EDGAR →ADTRAN announced its unaudited financial results for the second quarter ended June 30, 2026, via press release and investor presentation. The disclosure includes revenue of $281.1 million (up 6.1% year-over-year), GAAP diluted loss per share of $0.13, and forward guidance for Q3 2026 revenue and operating margin.
View raw filing on EDGAR →This is a clear earnings release disclosing Pediatrix Medical Group's quarterly financial results for the three and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the company "issued a press release announcing the results of its operations" and attaches the press release as Exhibit 99.1. The release reports net revenue of $488 million, net income of $40 million, diluted EPS of $0.49, and Adjusted EBITDA of $76 million for Q2 2026, along with six-month results and forward guidance for full-year 2026 Adjusted EBITDA of $280–$300 million. This is material to investors assessing the registrant's financial performance and operational trends.
View raw filing on EDGAR →Kimco Realty issued a press release on August 4, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing net income of $0.22 per diluted share, FFO of $0.46 per diluted share, and raising its 2026 full-year outlook. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →Bruker Corporation issued a press release on August 4, 2026, announcing financial results for the three and six months ended June 30, 2026. The disclosure includes Q2-26 revenue of $838.5 million (up 5.2% yoy), GAAP diluted loss per share of $(0.41), non-GAAP diluted EPS of $0.49, and updated FY2026 guidance for revenues of $3.54 to $3.57 billion and non-GAAP EPS of $2.10 to $2.15. This is a standard quarterly earnings release with detailed financial results and forward guidance, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →This is a quarterly earnings release for Q2 2026 (three months ended June 30, 2026) disclosing financial results including research and development expenses ($36.2M), general and administrative expenses ($10.5M), and net loss ($52.8M), along with cash position ($433.1M) and operational updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.
View raw filing on EDGAR →Larimar Therapeutics announced its second quarter 2026 financial results and operational highlights on August 4, 2026, disclosing a net loss of $32.8 million for Q2 2026 (versus $26.2 million for Q2 2025), cash position of $156.3 million, detailed expense breakdowns, cash runway projections, and material clinical milestones including initiation of a rolling BLA submission and expected Phase 3 dosing in Q3 2026.
View raw filing on EDGAR →This is a clear earnings release disclosing Beam Therapeutics' second quarter 2026 financial results. The filing explicitly states "On August 4, 2026, the Company issued a press release announcing its financial results for the quarter ended June 30, 2026" and includes condensed consolidated balance sheet and statement of operations data showing net loss of $122.7 million for Q2 2026 versus $102.1 million in Q2 2025, along with cash position, R&D and G&A expenses, and cash runway guidance through mid-2029. This is a material disclosure affecting investor assessment of the registrant's financial condition.
View raw filing on EDGAR →This is IQM Quantum Computers' first earnings release as a public company, disclosing first half and second quarter 2026 financial results (revenue of EUR 8.9 million, operating loss of EUR 60.5 million for H1 2026) along with full-year 2026 guidance (EUR 42–47 million revenue target). The exhibit includes consolidated financial statements (balance sheet, income statement, cash flow statement) and is explicitly titled "Half year financial report" dated August 4, 2026. This is a material event for a newly listed company establishing its public financial track record and forward guidance.
View raw filing on EDGAR →Xometry issued a press release on August 4, 2026 announcing its second quarter 2026 financial results for the period ended June 30, 2026. The disclosure includes consolidated revenue of $229 million (41% YoY growth), gross profit of $87.2 million (34% YoY growth), Adjusted EBITDA of $14.1 million, and forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings release with detailed financial highlights, business metrics, and outlook, furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →Palvella Therapeutics reported second quarter 2026 financial results, including R&D expenses of $12.5M, G&A expenses of $8.9M, a net loss of $21.9M ($1.52 per share), and a cash position of $250.6M as of June 30, 2026, along with operational and clinical development updates.
View raw filing on EDGAR →This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 as a press release exhibit. The disclosure includes condensed statements of operations, balance sheet data, R&D and G&A expenses, net loss per share, and cash position—all hallmarks of an earnings release. While the filing also mentions operational updates (clinical trial progress, executive appointments, name change), the core Item 2.02 disclosure is the quarterly financial results announcement.
View raw filing on EDGAR →ASP Isotopes disclosed a shareholder letter dated August 4, 2026, providing detailed operational and financial updates across multiple business divisions (PET Labs, Renergen, stable isotopes, QLE, Alpa Theranostics) in advance of the company's announcement of Q2 2026 financial results, including revenue guidance and EBITDA targets.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states "In a press release dated August 4, 2026, NexPoint Residential Trust, Inc. (the "Company") announced financial results for the Company's second quarter ended June 30, 2026." The exhibit contains comprehensive quarterly financial data including net loss, FFO, Core FFO, AFFO, revenues, NOI, and operational metrics, which are typical components of an earnings announcement. Material to investors as it discloses quarterly operating performance and guidance.
View raw filing on EDGAR →PSEG announced second quarter and six-month 2026 financial results on August 4, 2026, reporting net income of $0.67 per share for Q2 2026 and $2.15 per share for the six-month period, along with non-GAAP operating earnings guidance of $4.28–$4.40 per share for full-year 2026.
View raw filing on EDGAR →Millrose Properties announced Q2 2026 financial results ended June 30, 2026, reporting net income of $125.9 million ($0.76 per share), AFFO of $0.77 per share, and total revenues of $196.9 million. The company also declared a dividend of $0.77 per share.
View raw filing on EDGAR →This is a clear earnings release disclosing Expeditors' second quarter 2026 financial results. The filing explicitly states "On August 4, 2026, Expeditors International of Washington, Inc., a Washington corporation, issued a press release announcing second quarter 2026 financial results" and the attached Exhibit 99.1 is labeled "EARNINGS RELEASE" with detailed financial metrics including diluted EPS of $2.03 (up 51%), net earnings of $266 million (up 45%), operating income of $350 million (up 41%), and revenues of $3.5 billion (up 32%). This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →Red Rock Resorts issued a press release on August 4, 2026 disclosing second quarter 2026 financial results, including net revenues of $510.3 million (down 3.0% YoY), net income of $76.6 million (down 29.3% YoY), and Adjusted EBITDA of $208.0 million (down 9.3% YoY). The filing explicitly states "On August 4, 2026, the Registrant issued a press release" under Item 2.02 (Results of Operations and Financial Condition), with the press release attached as Exhibit 99.1 and incorporated by reference. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →This is a clear earnings release disclosing Syndax's financial results for Q2 2026 (quarter ended June 30, 2026), including total revenue of $73 million (92% YoY increase), Revuforj net revenue of $54.7 million (91% YoY increase), and Niktimvo collaboration revenue of $18.1 million (67% YoY increase). The press release and presentation are furnished as Exhibits 99.1 and 99.2 under Item 2.02, which is the standard Item for earnings disclosures. The results are material to investors as they demonstrate significant commercial traction for the company's two FDA-approved products.
View raw filing on EDGAR →Personalis issued a press release on August 4, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $22.4 million (30% YoY growth), clinical revenue of $2.6 million (442% YoY growth), and clinical test volume of 10,384 tests (199% YoY growth). The filing includes consolidated statements of operations, balance sheets, and supplemental revenue information, all hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states "Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial results including cash position ($353.9M), R&D expenses ($39.2M), G&A expenses ($9.8M), and net loss ($45.6M), along with condensed balance sheets and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →Green Thumb Industries issued a press release on August 4, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $306.7 million (up 4.6% YoY), GAAP net income of $4.9 million ($0.02 per share), and normalized EBITDA of $84.3 million. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings disclosure under Item 2.02 (Regulation FD Disclosure).
View raw filing on EDGAR →TransMedics issued a press release on August 4, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing total revenue of $189.9 million (21% increase YoY), net income of $14.7 million ($0.41 per diluted share), and raising full-year 2026 revenue guidance to $737–$757 million. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1.
View raw filing on EDGAR →This is a press release announcing Stevanato Group's Q2 2026 financial results, including revenue of €302.0 million (8% growth), gross profit margin of 28.7%, and adjusted EBITDA margin of 26.0%. The release also discloses the completed divestiture of Balda C. Brewer, Inc. and updated full-year 2026 guidance. While the exhibit contains both an earnings announcement and a material M&A event (the subsidiary sale), the primary and dominant disclosure is the quarterly earnings release, which is material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Zeta Global issued a press release on August 4, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 revenue of $443 million (44% Y/Y growth), positive GAAP net income of $8 million, and significantly increased full-year 2026 guidance across revenue, adjusted EBITDA, free cash flow, and EPS. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and forward outlook.
View raw filing on EDGAR →Sixth Street Specialty Lending disclosed Q2 2026 earnings results with net investment income of $0.43 per share, net income of $0.43 per share, and NAV per share of $16.24, along with comprehensive portfolio activity and debt metrics.
View raw filing on EDGAR →Mercury General Corporation issued a press release on August 4, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $263.5 million (Q2 2026) versus $166.5 million (Q2 2025), net income per diluted share of $4.76 versus $3.01, and a combined ratio of 89.9% versus 92.5%. The filing includes detailed consolidated highlights, investment results, balance sheet information, and operating ratios. This is a standard quarterly earnings release with comprehensive financial metrics and results of operations.
View raw filing on EDGAR →Fortune Brands issued a press release on August 4, 2026 reporting Q2 2026 financial results, including net sales of $1.2 billion (down 4.1% YoY), GAAP EPS of ($0.19), and updated full-year 2026 guidance. The disclosure is a standard quarterly earnings announcement with detailed segment results, balance sheet metrics, and forward guidance, furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →This is a clear earnings release disclosing Ultragenyx's financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $214 million, net loss of $92 million, and detailed product revenue breakdowns. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing also reaffirms full-year 2026 guidance and discusses upcoming clinical and regulatory catalysts.
View raw filing on EDGAR →Vroom disclosed Q2 2026 financial results for the quarter ended June 30, 2026, achieving a historic milestone with positive net income of $0.6 million and adjusted net income of $1.5 million for the first time in company history. The disclosure includes detailed financial tables, segment results, and management commentary furnished as a press release with supplemental investor presentation materials.
View raw filing on EDGAR →OnKure Therapeutics issued a press release on August 4, 2026, reporting financial results for the quarter ended June 30, 2026, including R&D expenses of $12.6 million, G&A expenses of $4.3 million, net loss of $15.3 million ($0.31 per share), and cash position of $176.4 million. The filing explicitly discloses Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →This exhibit is a Q2 2026 financial results presentation dated August 4, 2026, disclosing quarterly revenue of €280M (8% growth), adjusted EBITDA of €78.7M (21% growth), and adjusted diluted EPS of €0.14. The document presents segment performance, margin expansion, and updated full-year 2026 guidance, which are material to investors assessing the registrant's financial performance and outlook.
View raw filing on EDGAR →Devon Energy announced its second-quarter 2026 financial and operational results on August 4, 2026, with an earnings release and supplemental financial information furnished as Exhibits 99.1 and 99.2. The disclosure includes consolidated statements of earnings, cash flows, production data, capital expenditures, and forward-looking guidance—all hallmarks of a quarterly earnings release under Item 2.02. The company reported net earnings of $1.9 billion ($2.03 per diluted share) and core earnings of $1.5 billion ($1.57 per diluted share), along with operating cash flow of $3.7 billion and adjusted free cash flow of $1.7 billion.
View raw filing on EDGAR →BrightView issued a press release on August 4, 2026 reporting unaudited results for the third quarter ended June 30, 2026, disclosing net service revenues of $717.6 million, net income of $6.1 million, and Adjusted EBITDA of $96.1 million, along with updated fiscal year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02 of Form 8-K.
View raw filing on EDGAR →Champion Homes issued a press release on August 4, 2026, disclosing financial results for the first quarter fiscal 2027 ended June 27, 2026, including net sales of $710.2 million, gross profit margin of 25.2%, EPS of $0.89, and adjusted EBITDA of $73.6 million. The Board also approved a $50 million increase to the share repurchase program.
View raw filing on EDGAR →This is a clear earnings release disclosing Revolve Group's second quarter 2026 financial results, including net sales of $347.4 million (12% YoY growth), net income of $18.6 million (86% YoY growth), and operational metrics such as active customer growth of 11%. The press release is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial summaries, segment performance, cash flow analysis, and forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →Palomar Holdings issued a press release on August 4, 2026, announcing Q2 2026 financial results including net income of $52.6 million ($1.94 per diluted share), adjusted net income of $63.8 million ($2.36 per diluted share), gross written premiums of $630.5 million (27% increase), and full-year 2026 adjusted net income guidance of $270–$280 million.
View raw filing on EDGAR →This is a clear earnings release disclosing Gladstone Capital's financial results for the fiscal quarter ended June 30, 2026. The press release, filed as Exhibit 99.1 to the 8-K Item 2.02, presents comprehensive quarterly financial data including net investment income ($11.0 million, $0.49 per share), net asset value per share ($21.50), portfolio metrics, and management commentary. The disclosure is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Acadia's financial results for the six months ended June 30, 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $308 million (up 16% YoY), net income of $32 million, and updated full-year 2026 guidance to $1.24–$1.30 billion in total revenues. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure describes Kodak's second quarter 2026 financial results, including consolidated revenues of $311 million (18% YoY increase), gross profit of $82 million (61% increase), GAAP net income of $17 million (vs. a $26 million loss in Q2 2025), and Operational EBITDA of $36 million. The press release is furnished as Exhibit 99.1 and includes detailed financial statements and segment performance data. This represents material financial results that would affect a reasonable investor's assessment of the company's performance and trajectory.
View raw filing on EDGAR →The filing discloses Alphatec's second quarter 2026 financial results via a press release issued on August 4, 2026, as indicated in Item 2.02. The press release reports total revenue of $214 million (up 15% YoY), surgical revenue of $196 million (up 17%), GAAP net loss of ($26) million, and adjusted EBITDA of $36 million, along with reaffirmed and increased 2026 full-year guidance. This is a standard earnings release disclosure material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →The Hackett Group issued a press release on August 4, 2026 disclosing consolidated financial results for the second fiscal quarter ended June 26, 2026, including revenue of $69.3M, GAAP diluted EPS of $0.18, adjusted diluted EPS of $0.34, and forward guidance for Q3 2026.
View raw filing on EDGAR →Viasat disclosed its first quarter fiscal year 2027 financial results on August 4, 2026, including revenue of $1.2 billion (down 1% YoY), net loss of $52 million (improved from $56 million in Q1 FY2026), and adjusted EBITDA metrics. The disclosure includes a press release (Exhibit 99.1) and a detailed shareholder letter (Exhibit 99.2) with comprehensive financial and operational commentary, which is the standard format for an earnings release under Item 2.02.
View raw filing on EDGAR →LeMaitre Vascular issued a press release on August 4, 2026 disclosing preliminary Q2 2026 financial results, including net sales of $70.4mm (+10%), gross margin of 72.1%, operating income of $20.4mm (+26%), and diluted EPS of $0.74 (+23%), along with forward guidance for Q3, Q4, and full-year 2026. The filing includes condensed consolidated financial statements and is a classic Item 2.02 earnings disclosure.
View raw filing on EDGAR →